BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Releases FY2021 Financial Results

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, reported company results for three and twelve months ended May 31, 2021. Highlights of the report indicate the company saw net proceeds of $27.2 million through issuing common shares and the exercise of warrants and options as well as ending the fiscal year with cash and cash equivalents totaling $18.3 million. The company also reported a net loss of $10.2 million. Business highlights for the company included the development of iSTRYM, MINDCURE’s exclusive digital therapeutics tool. The software application is a first-of-its-kind, and the company has filed a provisional patent application covering iSTRYM, which clinicians can use in assisting the healing journey of patients before, during and after therapy sessions. MINDCURE also filed two provisional patent applications in association with the synthesis routes of its full chemical synthesis of ibogaine and began manufacturing synthetic ibogaine. Finally, the company made additions to its senior management team and board of directors; completed a strategic equity investment in ATMA Journey Centers Inc.; and completed a strategic equity investment in Awakn Life Sciences Inc. “MINDCURE’s first full year of operations was full of outstanding accomplishments and highlighted by the successful completion of several milestones,” said MINDCURE president and CEO Kelsey Ramsden in the press release. “The strategy and infrastructure we have put in place over the past year positions the company well to continue the development and release of our digital therapeutics platform, iSTRYM, and to continue our research for psychedelics. The company’s achievements could not have happened without the hard work and commitment of the entire MINDCURE team, our board of directors and our advisors. I would like to especially thank our investors for seeing and supporting the vision and execution at MINDCURE.”

To view the full press release, visit https://ibn.fm/FymNz

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.

NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork